- DKK9.36bn
- DKK9.11bn
- DKK407.87m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 38.22 | ||
| PEG Ratio (f) | 2.79 | ||
| EPS Growth (f) | 15.89% | ||
| Dividend Yield (f) | 0.56% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 15.66 | ||
| Price to Tang. Book | 20.14 | ||
| Price to Free Cashflow | 73.03 | ||
| Price to Sales | 20.37 | ||
| EV to EBITDA | 39.8 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 34.62% | ||
| Return on Equity | 30.83% | ||
| Operating Margin | 45.77% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | DKKm | 214.1 | 281.13 | 428.39 | 444.4 | 407.87 | 527 | 605.5 | 18.37% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +30.11 | +47.92 | +77.12 | +12.13 | -23.75 | +55.08 | +15.89 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Chemometec A/S is a Denmark-based company engaged in the development, manufacture and sale of analytical instruments used for quantitative analysis of cells in liquids. The Company’s activities are divided into three business areas: Instruments, which offers a range of NucleoCounter analytical instruments for counting mammalian, animal, yeast and sperm cells, as well as somatic cells in milk, among others; Consumables, which distributes disposable cassettes, solutions, reagents and slides; and Other, which is responsible for the partnership development in a number of research projects, among others. The Company’s analytical products are based on a technology, which combines fluorescence microscopy with digital imagery. Its customer portfolio comprises entities active primarily within pharmaceutical, food processing and agriculture industries. Furthermore, the Company is a parent of ChemoMetec USA Inc.
Directors
- Preben Koenig CHM (70)
- Steen Soendergaard-Larsen CEO (61)
- Martin Glensbjerg VCH (61)
- Bent Faurskov CFO
- Christopher Runchel SVP
- Soeren Kjaerulff VRD
- Lisbet Helles OTH
- Kurt Nielsen OTH
- Michael Packert OTH
- Louise Petersen OTH
- Kristine Faerch DRC
- Peter Reich IND (57)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 2nd, 1997
- Public Since
- December 18th, 2006
- No. of Shareholders
- 13,037
- No. of Employees
- 184
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
OMX Nordic Exchange - Copenhagen- Shares in Issue
- 17,402,479
- Address
- Gydevang 43, ALLEROED, 3450
- Web
- https://chemometec.com/
- Phone
- Auditors
- Deloitte Statsautoriseret Revisionspartnerselskab
Upcoming Events for CHEMM
Chemometec A/S Annual Shareholders Meeting
Q1 2026 Chemometec A/S Earnings Release
Similar to CHEMM
Ambu A/S
OMX Nordic Exchange - Copenhagen
Bactiquant A/S
OMX Nordic Exchange - Copenhagen
BioPorto A/S
OMX Nordic Exchange - Copenhagen
Coloplast A/S
OMX Nordic Exchange - Copenhagen
Demant A/S
OMX Nordic Exchange - Copenhagen
FAQ
What is the ChemoMetec A/S share price?
As of Today at 19:54 UTC, shares in ChemoMetec A/S are trading at DKK538.00. This share price information is delayed by 15 minutes.
How has the ChemoMetec A/S share price performed this year?
Shares in ChemoMetec A/S last closed at DKK538.00 and the price had moved by +45.41% over the past 365 days. In terms of relative price strength the ChemoMetec A/S share price has outperformed the FTSE Global All Cap Index by +39.34% over the past year.
What are the analyst and broker recommendations for ChemoMetec A/S?
The overall consensus recommendation for ChemoMetec A/S is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the ChemoMetec A/S dividend yield?
The ChemoMetec A/S dividend yield is 0.74% based on the trailing twelve month period.
Does ChemoMetec A/S pay a dividend?
Last year, ChemoMetec A/S paid a total dividend of DKK4.00, and it currently has a trailing dividend yield of 0.74%. We do not have any data on when ChemoMetec A/S is to next pay dividends.
When does ChemoMetec A/S next pay dividends?
We do not have data on when ChemoMetec A/S is to next pay dividends. The historic dividend yield on ChemoMetec A/S shares is currently 0.74%.
How do I buy ChemoMetec A/S shares?
To buy shares in ChemoMetec A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ChemoMetec A/S?
As of the previous close price of DKK538.00, shares in ChemoMetec A/S had a market capitalisation of DKK9.36bn.
Where are ChemoMetec A/S shares listed?
Here are the trading details for ChemoMetec A/S:
- Country of listing: Denmark
- Exchange: CPH
- Ticker Symbol: CHEMM
What kind of share is ChemoMetec A/S?
Based on an overall assessment of its quality, value and momentum ChemoMetec A/S is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ChemoMetec A/S share price forecast for 2025?
The analyst consensus target price for shares in ChemoMetec A/S is DKK598.33. That is 11.21% above the last closing price of DKK538.00.
Analysts covering ChemoMetec A/S currently have a consensus Earnings Per Share (EPS) forecast of DKK12.15 for the next financial year.
Find out moreWhat is the trend in the ChemoMetec A/S share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ChemoMetec A/S. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -8.43%.
As of the last closing price of DKK538.00, shares in ChemoMetec A/S were trading +9.02% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ChemoMetec A/S PE Ratio?
The ChemoMetec A/S PE ratio based on its reported earnings over the past 12 months is 38.22. The shares last closed at DKK538.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ChemoMetec A/S?
ChemoMetec A/S' management team is headed by:
- Preben Koenig - CHM
- Steen Soendergaard-Larsen - CEO
- Martin Glensbjerg - VCH
- Bent Faurskov - CFO
- Christopher Runchel - SVP
- Soeren Kjaerulff - VRD
- Lisbet Helles - OTH
- Kurt Nielsen - OTH
- Michael Packert - OTH
- Louise Petersen - OTH
- Kristine Faerch - DRC
- Peter Reich - IND